Use of High‐Throughput Proteomic Arrays for the Discovery of Disease‐Associated Molecules

Abstract

The high‐throughput proteomics approach is the natural progression of the genome sequencing projects of the 1990s. Organisms such as M. tuberculosis with 4000 ORFs, or malaria ( P. falciparum and P. vivax ) with even larger genomes, can now be assayed on a whole‐proteome scale. This article focuses on assay miniaturization technology and applications of advances in cloning and gene expression in profiling the immune response to infection, cancer, and autoimmune disease.